NanoSphere Health Offers Six-Fold Improvement in Cannabinoid Bioavailability
The U.S. cannabis industry is projected to exceed $50 billion in size over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis in California and other states. While there are many opportunities for investors in the space, since they generate high-margin licensing revenue and don’t touch the plant, biotech firms developing innovative delivery mechanisms offer investors a compelling opportunity.
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) has developed an innovative delivery technology that solves key issues related to cannabinoid bioavailability. With an existing licensing agreement, the company is also well on its way to commercialization after spending more than a decade fine-tuning its technology–and developing products that have applications across an array of industries. Investors may want to take a closer look at the stock as a potential opportunity in the space.
The issue of bioavailability is a major problem facing the medical cannabis industry. In a 2009 study, researchers found that cannabinoid bioavailability ranged from 2-56 percent for inhaled cannabis smoke and from 4-20 percent for orally consumed cannabis products. This variability among patients makes it difficult for physicians to prescribe cannabinoid-based products.
On a broader level, pharmaceutical industry experts estimate that approximately 40 percent of lipophilic (fat-soluble) medications fail in clinical trials because of their lack of water solubility and formulation instability. The insolubility, degeneration by digestive enzymes, pre-systemic metabolism, poor intestinal absorption, and removal from the liver prevents them from reaching threshold levels for activity. To a great extent, this first-pass metabolism also affects cannabinoid absorption.
Many companies have started developing cannabinoid delivery mechanisms aimed at improving bioavailability. But it’s a challenging task that requires extensive research and development. After developing these delivery mechanisms, they must also work to integrate them with existing cannabinoid products, which requires the participation of other cannabis industry participants. These challenges have left a gaping hole in the market for a reliable solution.
Researchers at NanoSphere Health have spent the past decade developing its patent-pending NanoSphere Delivery System™. The product successfully addresses the absorption issues associated with a wide variety of products, such as nutraceuticals, pharmaceuticals, over-the-counter medications, phytonutrients, and cannabinoids. Only recently did the company decide to enter the burgeoning cannabis industry, where its technology adapts seamlessly as a solution to questions surrounding pharmaceutical bioavailability.
The evidence-based NanoSphere Delivery System™ provides up to six times the bioavailability of conventional cannabinoids by transporting active ingredients directly into the bloodstream and cells using patent-pending natural lipid nanoparticle structures. In addition to the bioavailability improvements, the platform offers a high degree of biocompatibility, versatility, efficacy, and safety that makes it a natural choice for industry participants.
On January 23, the company announced that it signed an agreement to license its technology in the State of California. The Oakland-based licensee is a private-label manufacturer of pharmaceutical goods for more than 35 leading brands in the legal cannabis space and the agreement provides the manufacturer with a non-exclusive license to the patent-pending NanoSphere Delivery System™ and its branded Evolve NanoSerum line.
NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) represents a compelling investment opportunity in the legal cannabis industry. In addition to solving key issues relating to bioavailability, the company has already started to see some commercial wins after signing a deal with a large private-label manufacturer of pharmaceutical goods for more than 35 leading cannabis brands in the State of California.
Investors may want to take a closer look at the stock as a potential opportunity in the burgeoning cannabis industry, and in particular, California’s rapidly growing market.